Moderna, Inc. (FRA:0QF)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.01B |
| Revenue (ttm) | 2.62B |
| Net Income (ttm) | -2.47B |
| Shares Out | n/a |
| EPS (ttm) | -6.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,010 |
| Average Volume | 13,387 |
| Open | 20.52 |
| Previous Close | 20.66 |
| Day's Range | 20.52 - 20.80 |
| 52-Week Range | 20.34 - 72.50 |
| Beta | n/a |
| RSI | 34.57 |
| Earnings Date | Nov 6, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
FDA approves COVID-19 vaccines only for 'high risk' people
The Food and Drug Administration (FDA) on Wednesday approved the updated version of Pfizer's and Moderna's COVID-19 vaccines for this upcoming respiratory viral season, but limited the approval to sen...
FDA approves updated Covid vaccines with tighter access rules
The FDA has approved updated COVID-19 vaccines for the 2025-2026 season, with stricter eligibility rules focusing on older adults and high-risk individuals. Pfizer-BioNTech's shot is for those 65 and ...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr . Sho...
30 Stocks That Could Rally 30% or More
Analysts say these S&P 500 stocks have at least 30% price upside over the next year or so.
Moderna Stock Is Trading Higher Friday: What's Going On?
Full story available on Benzinga.com
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has autho...
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has autho...
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences:Morgan Stanley's 23rd Annual Global Hea...
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global He...
Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock
NIH cancels mRNA vaccine contracts, citing lack of public trust
National Institutes of Health Director Jay Bhattacharya claims the federal government recently cancelled millions of dollars' worth of mRNA research contracts because the general public does not trust...
FDA may pull authorization for Pfizer COVID shot for kids under 5
The Food and Drug Administration (FDA) is considering revoking the authorization of Pfizer’s COVID-19 vaccine for healthy children under 5 years old, the company confirmed Wednesday. The move would ad...
Moderna Options Trading: A Deep Dive into Market Sentiment
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ: MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available opt...
Bhattacharya and Kennedy split on mRNA cuts
What's Driving the Market Sentiment Around Moderna?
Moderna's (NYSE: MRNA) short percent of float has fallen 4.88% since its last report. The company recently reported that it has 63.02 million shares sold short , which is 22.63% of all regular shares...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
View Preview Pfizer Inc.'s (NYSE: PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and pro...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...
The 3 Things That Matter for Moderna Now
The company is still trying to prove that it isn't just a pandemic play.
RFK Jr has slashed vaccine research. You need to know how perilous that is for the world | Devi Sridhar
The avian flu virus is now just one mutation away from easier transmission among humans. Donald Trump’s health chief is a grave risk to world health Prof Devi Sridhar is chair of global public health ...
Pfizer Covid vaccine for young children may not be renewed by FDA
Email obtained by Guardian says Pfizer was told approval may not be granted, meaning Moderna may have to fill gap Pfizer’s Covid vaccine for young children may not be renewed by the US Food and Drug A...
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals
Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company’s vaccines and said it would cancel some contracts and stop fundi...